First Tracks Biotherapeutics, Inc. (TRAX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

First Tracks Biotherapeutics, Inc. (TRAX) closed at USD 34.13 on 2026-10-14, a change of +79.6 % over the past year, with a market capitalization of USD 1.29B.

First Tracks Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

First Tracks Biotherapeutics, Inc. key figures

Previous close

USD 34.13 (2026-10-14)

1-year change

+79.6 %

Market cap

USD 1.29B

Enterprise value

USD 1.12B

P/E ratio (trailing)

-7.65

P/E ratio (forward)

-10.06

EPS (trailing)

-4.71

EPS (forward)

-3.58

PEG ratio

n/a

Price to book

7.56

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.05

Employees

104

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for First Tracks Biotherapeutics, Inc. and compare it with other stocks.